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Abstract 
Objective: To analyze the effect of emodin on blood glucose and body weight in rats 
with type 1 diabetes. 
Methods:A total of 45 healthy SD rats were selected followed by being adaptively 
fed for one week and then from them 15 rats were randomly selected out as the 
control group and the remaining 30 healthy SD rats were given intraperitoneal 
injection of streptozotocin to establish diabetic model with the control group receiving 
intraperitoneal injection of citrate buffer solution  of same doses; At the fifth day, the 
rats were fasted for 6h and appropriately fed with water. Then the tail blood was 
collected to measure the fasting blood glucose of rats and this step was repeated 15d 
after the injection of streptozotocin. The diabetic rat model was established 
successfully when the blood glucose was detected to be no less than 
16.9mmol/L;Thirty diabetic model rats were randomly divided into diabetes group 
and emodin group with 15 cases in each group( n = 15); 15d later, the rats in diabetes 
group and control group were treated with intragastric administration of PBS, 5ml/kg , 
and the rats in emodin group were given intragastric administration of emodin 
suspension (8g/L),5ml/kg. The changes of fasting blood glucose and body weight 
were observed and compared in three groups from the time point of before model 
establishment to 10 weeks after successful establishment of model.  
Results: There was no significant difference among three groups in fasting blood 
glucose and body weight at the initial stage of establishing model; In diabetes group 
and emodin group, the   rat’s body weight in T2 was significantly lower than that in 
T1 with the body weight decreasing more significantly in diabetes group (P<0.05), 
while the blood glucose in T2 was significantly higher than that in T1 with the blood 
glucose increasing more significantly in diabetes group (P<0.05).  
Conclusion: Emodin can relieve hyperglycemia in type I diabetic rats but has little 
influence on body weight. 
Keywords: type 1 diabetes ; rats; emodin; body weight; blood sugar 
 
Introduction 
Diabetes, more common in endocrine system diseases, is most often diagnosed in 
middle and elder age group but recent medical survey reveals its incidence has 
increased year by year in young people. According to a study in 2013, the number of 
diabetic patients has been close to 400 million in the adults of the world, which 
seriously threatens people's lives and health[1-3]. Emodin is an orange-yellow needle 
crystal, orange in acetone and yellow in methanol. Its melting point reaches 256℃～
257℃ with specific reaction of anthraquinone. It is the main active ingredient of 
rhubarb almost insoluble in water but soluble in ethanol and alkali solution. Emodin 
can inhibit the transportation of sodium and potassium ion from intestine to cell, cause 
water retention in the intestine, stimulate peristalsis and thereby play the function of 
diarrhea with weak effect. The in vivo distribution and pharmacokinetic study show 
 that when the rats were given gastric infusion of  14C emodin at the dose of 50mh/kg, 
the excretion in urine is 18% of the dose given within 24 hours and 22% of the given 
dose with 72 hours. Most of the rhein in the urine are excreted within 24 hours. There 
are very few metabolites in urine 72 hours after administration and they appear to 
exist mainly in the free,unbounded form. The total of emodin and rhein reaches 16% 
of given doses, the content of glucose aldehyde or sulfate is only about 3% in emodin 
with another 3% of other radioactive residues. Within 24 hours and 120 hours after 
administration, the emodin in the stool is mainly in free state, accounting for 
respectively 48% and 68% of given dose. Six hours after administration,the emodin 
has high concentration in bile excretion and the excretion reaches  49% of given 
dose within 15 hours. The emodin appearing to exist mainly in the form of glucuronic 
acid ester or sulfate accounts for 70% and the radioactivity of most organs decreases 
obviously 3~5 days after administration, but until the fifth day there remains a very 
high radiation activity in the kidney. The radioactivity of the mesentery and adipose 
tissue increases greatly 72~120 hours after administration. Within 0~48 hours after 
gavage administration of emodin at the dose of 91mg/kg in the rats, the overall yield 
of anthraquinone derivatives excreted through   urinary and feces is up to 53% of 
given dose in which the total amount of excretion in urine and feces is 2% in 0~24 
hours. The total anthraquinone derivatives in the bile reach a peak 4 hours after 
administration and then decrease gradually. Bile is one of major routes of emodin 
excretion. 
Modern pharmacological studies have shown that emodin has the function of 
anti-inflammation, improving microvascular disease, improving immunity, promoting 
recovery of blood lipid metabolism and relieving insulin resistance. In recent years, 
medical research has found that emodin can reduce the blood sugar concentration of 
diabetic rats and cause weight loss but there are few studies on its effect of type 1 
diabetes mellitus[4-7]. The aim of this study was to investigate whether emodin can 
cause changes in body weight and blood sugar in type 1 diabetic rats based on the 
association between emodin and type 1 diabetes mellitus. 
 
Data and methods 
General data 
A total of 50 healthy SD rats were selected. They all were male and weighted 
198-205g,  (200.54  1.74) g on the average, 3-month old with the fasting blood 
glucose of (5.48  0.32) mmol/L. 
Research instruments and reagents 
The reagents applied this study mainly included streptozotocin, emodin, glucose 
detector and citric acid buffer. Among them, the citric acid buffer was made as follow: 
(1) citric acid plus Shuangyan water and sodium citrate plus Shuangyan water were 
made respectively into A and B liquid, shown as table , equal amount of which then 
were mixed with pH value adjusted to 4.2-4.5 as the citric acid buffer used in the 
study. Mixture of STZ and citric acid buffer was made in the proportion of 1:100 as C 
liquid. 
 
 Table 1 Mixture of A and B liquid 
 mixture  Reagent 1 dosage Reagent 2 dosage 
A liquid citric acid 2.10g Shuangyan 
water 
100ml 
B liquid sodium citrate  2.94g Shuangyan 
water 
100ml 
1.3 establishment of type I diabetic rat model 
A total of 45 healthy SD rats were adaptively fed for one week and the tail blood was 
collected to measure the fasting blood glucose, which showed normal value. Then 15 
from 45 rats were randomly selected out as the control group and the remaining 30 
healthy SD rats were given intraperitoneal injection of C liquid with the dosage 
calculated in accordance with the dose of 65mg/kg in streptozotocin and the rat’s 
weight to establish diabetic rats model and the control group were injected with citrate 
buffer of the same dose; At the fifth day, the rats were fasted within previous 12h and 
appropriately fed with water. Then the tail blood was collected to measure the fasting 
blood glucose of rats and this step was repeated 15d after the injection of 
streptozotocin. The diabetic rat model was successfully established when the blood 
glucose was detected to be no less than 16.9mmol/L shown as in Table 2. In this study, 
15d after the beginning of model construction, 30 rats was successfully modeled with 
the success rate of 100.00%[8-10]. 
Table 2 Analysis of fasting blood glucose concentration before and after establishment 





statistic P  value 
before 
establishment 
5.68 0.22 —— —— 
the fifth day  
after establishment 
16.28 1.46 1t =50.0937 1P =0.0000 
the fifteenth day 
after establishment 
24.88 2.39 2t =56.5661 2P =0.0000 
Note: 1t and 1P represented the statistical value of the comparison between before 
establishment and 5d after establishment and 2t , 2P represented the statistical value of 
the comparison between before establishment and 15d after establishment  
Grouping experiment 
Thirty diabetic model rats were randomly divided into diabetes group and emodin 
group with 15 cases in each group( n = 15); 15d later, the rats in diabetes group and 
control group were treated with intragastric administration of PBS, 5ml/kg , and the 
rats in emodin group were given intragastric administration of emodin suspension 
(8g/L),5ml/kg. The changes of fasting blood glucose and body weight were observed 
and compared in three groups from the time point of before model establishment to 10 
weeks after successful establishment of model with T1 representing the former time 
point and T2 the latter[11-15]. 
 Statistical analysis 
SPSS13.0 statistical software was selected in the study for data processing. The 
measurement data were described as “ sx  ” and checked by t test, P <0.05 suggested 
there was obvious difference in the data of statistical significance. 
 
Results 
General physiological condition of rats before and after establishment of type 1 
diabetes model 
Before the establishment of type 1 diabetes model, the rats in the diabetic group were 
able to move freely with glossy fur and sensitive response. After injection of C they 
were listless with the furs gradually turning yellow and the body weight slowly 
decreasing.Besides the consumption of  edible feed and intake of water increased 
gradually with rising excretion. With rather damp bedding, the rats were subjected to 
reduced activity, lags in response and moderate sensitiveness. 
The rats in the emodin group had the same performance as those in the diabetes group 
before intragastric administration of emodin suspension while after the administration 
they remained dispirited and gradually angular with dim and relatively loose fur. 
Their reaction was not flexible with slow movement and some rats showed hair loss 
on the back with especially serious failure  occasional seen. 
The rats in the control group did not change significantly before and after the model 
establishment, Their activity changed little with the consumption of food and water as 
well as urine and stool remaining unchanged. There were not obvious changes in the 
rats’ daily state. 
Changes in blood glucose and body weight before and after the establishment of type 
1 diabetes model 
There was no significant difference in fasting blood glucose and body weight among 
the three groups in the initial stage of model construction; the rat weight of diabetes 
group and emodin group was obviously lower compared with the result 10 weeks 
after successful model construction with the weight in the diabetes group decreasing 
more significantly (P<0.05): (1) comparison between T2 and T1 in diabetes group: 
t=3.8607, P=0.0006; (2)comparison of T2 between diabetes group and control group:t 
=32.4768,P =0.0000; (3) comparison between T2 and T1 in emodin group:t=4.2950, 
P=0.0002; (4) comparison of T2 between emodin group and control group:t=7.2111, 
P=0.0000; (5)comparison of T2 between diabetes group and emodin group:t=0.9813, 
P=0.3316. 
The blood glucose of diabetes group and emodin group was significantly higher than 
that before model construction with higher ascending range seen in the diabetes 
group(P<0.05): (1) comparison between T2 and T1 in diabetes group,t=27.4976, 
P=0.0000; (2)comparison of T2 between diabetes group and control group: t=27.4700, 
P=0.0000; (3)comparison between T2 and T1 in emodin group:t=7.3288, P=0.0000; 
(4)comparison of T2 between emodin group and control group:t =7.2111,P =0.0000;; 
(5)comparison of T2 between diabetes group and emodin group:t=3.7007,P =0.0009 
shown in Table 3. 
 
 Table 3 blood glucose and weight changes in rats before and after model 
construction 
group 
blood glucose （mmol/L） weight （g） 
T1 T2 T1 T2 
control group: 5.55 0.36 5.58 0.41 200.35 4.87 421.22 3.96 
diabetes group 5.68 0.22 29.87 3.40 200.02 3.03 170.30 29.66 
emodin group 5.33 0.35 21.22 8.39 199.39 6.36 179.22 18.51 
 
Discussion 
Diabetes mellitus has a moderately high incidence in clinical findings with many 
triggering factors like heredity, environment and autoimmunity. The study of diabetic 
medicine involves many different kinds of experimental animals such as dogs, rabbits 
and pigs in which the rat is most commonly used with fast growth, low cost and easy 
cultivation as well as obtainment. In this regard the SD rat one of large numbers of 
species with is highest use rate. STZ has a specific function of destruction on 
pancreatic beta cells, which can lead to the decrease of insulin secretion and induce 
type I diabetes mellitus[16-20]. At present,it is the most commonly used model for 
type I diabetes mellitus in medical research with the advantages of high success rate 
in model construction and moderately low toxicity in animal tissue. In this course the 
use of STZ is one of the most critical step and when the injection volume of STZ is 
less than 40mg/kg,it will give rise to the failure of model establishment. In this study, 
STZ was injected intraperitoneally into rats at the dosage of 65mg/kg and the success 
rate of model establishment was 100%. 
Emodin, a kind of anthraquinones, is one of effective components of herbal medicine 
rhubarb after refinement, It can protect the nerve with prevention as well as treatment 
of Alzheimer's disease and also has the function of antibiosis, anti-inflammatory, 
antivirus and antitumor. Besides it can effectively induce part of cells to cause their 
apoptosis with the effect of reducing blood sugar and regulating lipid and inhibiting 
immune system activity. According to literature reports, emodin has the effect of 
AMPK activation and enables to increase glycolysis rate as well as accelerate glucose 
metabolism in vivo. It should be noted that emodin has certain toxicity, especially the 
high concentration of emodin will damage the liver and kidney, but it has little effect 
on the results of this study[21-23]. 
In the study we selected 45 healthy SD rats as the objects and divided them into 
control group ,diabetes group and emodin group with 15 rats included in each; among 
them, type 1 diabetic rat model was constructed by intraperitoneal injection of STZ 
followed by intragastric administration as the establishment of emodin group. The 
changes of fasting blood glucose and body weight were observed and compared in 
three groups from the time point of before model establishment to 10 weeks after 
successful establishment of model. It turned out that there was no significant 
difference among three groups in fasting blood glucose and body weight at the initial 
stage of establishing model; In diabetes group and emodin group, the rat’s body 
weight in T2 was significantly lower than that in T1 with the body weight decreasing 
more significantly in diabetes group (P<0.05), while the blood glucose in T2 was 
 significantly higher than that in T1 with the blood glucose increasing more 
significantly in diabetes group (P<0.05), suggesting that emodin can alleviate 
hyperglycemia in type 1 diabetic rats but has little effect on body weight. 
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